Table 1.
Reduced vaccine coverage due to COVID-19 in different parts of the world
| Authors | Site | Comparison | Vaccine of concern | Vaccine coverage (as number of beneficiaries) |
|---|---|---|---|---|
| Agrawal et al.[8] | India | February 2020 vs August 2020 | Birth dose-BCG, OPV, Hep B | Decline of 27.9% |
| MR-1 | Decline of 68.42% | |||
| MR-2 | Decline of 84.3% | |||
| DPT b2 | Decline of 57.4% | |||
| Chandir et al.[21] | Pakistan | Baseline (September 23, 2019 to March 22, 2020) vs Lockdown (March 23, 2020 to May 9, 2020) | BCG | Decline of 56.6% |
| OPV-0 | Decline of 51.6% | |||
| Penta-1 | Decline of 56.4% | |||
| OPV-1 | Decline of 56.2% | |||
| PCV-1 | Decline of 56.4% | |||
| Rota-1 | Decline of 56.1% | |||
| Penta-2 | Decline of 51% | |||
| OPV-2 | Decline of 50.7% | |||
| PCV-2 | Decline of 51.1% | |||
| Rota-2 | Decline of 50.7% | |||
| Penta-3 | Decline of 49.5% | |||
| OPV-3 | Decline of 49.2% | |||
| IPV | Decline of 51.6% | |||
| PCV-3 | Decline of 49.7% | |||
| Measles-1 | Decline of 47.4% | |||
| Measles-2 | Decline of 48.2% | |||
| Mansour et al.[25] | Lebanon | October 2019 vs March 2020 | OPV | Decline of 28% |
| IPV | Decline of 17% | |||
| Measles | Decline of 38% | |||
| Penta | Decline of 14% | |||
| PCV13 | Decline of 14% | |||
| Bramer et al.[26] | United States | Baseline (May 2016 to May 2019) vs May 2020 | Recommended vaccines for children aged ≤24 months | Decline of 15.5% |
| Buonsenso et al.[27] | Sierra Leone | Baseline (March 1, 2019 to April 26, 2019) vs Lockdown (March 1, 2020 to April 26, 2020) | BCG | Decline of 52.7% |
| OPV-0 | Decline of 52.7% | |||
| OPV-1 | Decline of 70.7% | |||
| Penta-1 | Decline of 70.7% | |||
| PCV-1 | Decline of 70.7% | |||
| Rota-1 | Decline of 70.7% | |||
| OPV-2 | Decline of 78.9% | |||
| Penta-2 | Decline of 78.9% | |||
| PCV-2 | Decline of 78.9% | |||
| Rota-2 | Decline of 78.9% | |||
| Penta-3 | Decline of 77.6% | |||
| PCV-3 | Decline of 77.6% | |||
| IPV | Decline of 77.6% | |||
| Measles | Decline of 65.6% | |||
| Langdon-Embry et al.[28] | Unites States | April 5 to 11, 2019 vs April 5 to 11, 2020 | Recommended vaccines for children aged <24 months | Decline of 62% |
| McDonald et al.[29] | Canada | Week 1 to 17, 2019 vs Week 1 to 17, 2020 | Hexavalent | Decline of 3.5% |
| MMR-1 | Decline of 3.7% | |||
| Harris et al.[12] | SEAR/WPR region | 2019 vs 2020 | DPT | Decline of 42% |
| OPV-infancy | Decline of 79% | |||
| OPV-school entry | Decline of 4% | |||
| IPV | Decline of 29% | |||
| Measles | Decline of 9% | |||
| Tessier et al.[30] | England | First four weeks 2019 vs first four weeks 2020 | Hexvalent-1 | Decline of 11.6% |
| MMR-1 | Decline of 7.5% | |||
| First four weeks 2020 vs first four weeks 2021 | Hexvalent-1 | Decline of 14.2% | ||
| MMR-1 | Decline of 19.3% |
BCG: Bacillus Calmette-Guérin; OPV: Oral polio vaccine; Hep: Hepatitis; MR: Measles Rubella vaccine; DPT: Diphtheria, Pertussis Tetanus vaccine; b: booster; PCV: pneumococcal conjugate vaccine; Penta: Pentavalent vaccine; Rota: Rotavirus vaccine; IPV: inactivate poliovirus vaccine; MMR: measles, mumps, and rubella vaccine